Acute myeloid leukemia

PTPN11 mutations are associated with poor outcomes across myeloid malignancies

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Distribution of co-occurring somatic gene mutations in PTPN11-mt cohort.


  1. 1.

    Kadia TM, Jain P, Ravandi F, Garcia-Manero G, Andreef M, Takahashi K, et al. TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes. Cancer. 2016;122:3484–91.

    CAS  Article  Google Scholar 

  2. 2.

    Stevens BM, Jones CL, Winters A, Dugan J, Abbott D, Savona MR, et al. PTPN11 mutations confer unique metabolic properties and increase resistance to venetoclax and azacitidine in acute myelogenous leukemia. Blood. 2018;132:909.

    Article  Google Scholar 

Download references

Author information




DMS wrote manuscript, all authors contributed patients and or collected data and interpreted results. All authors approved final manuscript.

Corresponding author

Correspondence to David M. Swoboda.

Ethics declarations

Conflict of interest

DMS, NAA, OC, JS, and MH declare no conflict of interest. EP obtains research funding from Incyte, Kura Oncology and BMS and has received Honorari a from Novartis. ATK is on advisory boards for Blueprint Medicines, Novartis and Prelude and has been part of a speaker’s bureau for BMS. CT is on advisory boards for Abbvie, Celgene, Pfizer, BMS and Novartis and has been part of a speaker’s bureau for Astellas, BMS and Jazz. KS is on advisory committees for Takeda, BMS, Novartis, Agios. She has received research funding from Incyte and has received Honoraria from Stemline and Astellas. JEL has done consulting for AbbVie, Agios, Astella, Daiichi Sankyo, ElevateBio, Jazz and received Honoria from Agios. DAS has received research funding from Celgene and Jazz and done consulting for Celyad, Incyte, Novartis, Agios, BMS, Intellia, Kite and Syndax. RSK has been part of a speaker’s bureau for Jazz, BMS and Agios and received honoraria from Abbvie, Incyte, Acceleron, Novartis and Geron.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Swoboda, D.M., Ali, N.A., Chan, O. et al. PTPN11 mutations are associated with poor outcomes across myeloid malignancies. Leukemia (2020).

Download citation